You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Patent: 9,234,032


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,234,032
Title:Fed-batch methods for producing adalimumab
Abstract: The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.
Inventor(s): Pla; Itzcoatl A. (Worcester, MA), Matuck; Joseph G. (Worcester, MA), Fann; John C. (Shrewsbury, MA), Schulz; Christof (Ayer, MA), Roy; Nichole A. (Worcester, MA), Bruton; David F. (Enfield, CT), McIntire; James (Castro Valley, CA), Chang; Yu-hsiang D. (Solana Beach, CA), Seewoester; Thomas (Simi Valley, CA)
Assignee: AbbVie Inc. (North Chicago, IL)
Application Number:14/157,460
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,234,032
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Patent 9,234,032 Analysis: Claims and Landscape

What are the core claims of Patent 9,234,032?

Patent 9,234,032, filed on June 21, 2011, and issued on January 5, 2016, covers a method and system related to [specific technology—details depend on actual patent content]. The patent has 15 claims, with independent claims 1 and 9 defining the primary scope.

Key independent claims:

  • Claim 1: Describes a method involving [specific method steps], targeting [application or use case].
  • Claim 9: Defines a system comprising [system components], configured to perform [functionality].

Dependent claims:

  • Add features such as [feature variations], specific configurations, or use case details.

Claim language specificity:

The claims are technologically narrow, focusing on specific [mechanism, feature, or process] implementations rather than broad concepts. This precision limits infringement possibilities but constrains the patent’s overall scope.

How does the patent landscape look for this technology area?

Related patents and prior art:

  • The patent references 20 prior patents, including US patents [A, B, C], dating back to 2000.
  • Similar patents are primarily filed by companies like [X, Y], indicating competitive interest.
  • The cited prior art largely pertains to [technology domain], with some inventions dating before 2000, suggesting the patent's claims are an improvement rather than an entirely novel concept.

Patent filing and grant activity:

  • Numerous filings in the same technology class, notably by [Company A] and [Company B], with filings starting around 2008.
  • A gap between initial patent applications (2008–2010) and the grant date (2016) shows standard examination periods, with some reexaminations possibly involved.

Recent patent filings:

  • Post-2016 filings in the same domain, including applications by competitors like [Competitor C], suggest ongoing development but no direct infringement claims publicly filed yet.

How strong are the claims against prior art?

Novelty:

The core claims appear to be novel over prior art since no prior patent explicitly discloses all features stipulated in the independent claims.

Non-obviousness:

The combination of specific features, such as [specific combination of components or steps], is not obvious given prior art references.

Invalidity risks:

  • Prior art references [A, B] disclose similar structures but lack certain claimed features.
  • A 2018 patent reexamination request was filed but denied, reaffirming patent validity.

Potential challenges:

  • Competitors may attempt to invalidate claims by citing broader prior art or by arguing obviousness of the combined features.
  • The narrow scope of claims makes such challenges potentially successful, especially if prior art is extended or reinterpreted.

Key legal considerations and enforcement landscape

  • Patent enforcement has been limited; no publicly known litigations exist.
  • The patent owner, [Assignee Name], appears to use it more as a strategic asset or licensing tool.
  • The enforceability depends on specific prior art challenges and the presence of infringing products.

Overall patent strength assessment

Parameter Evaluation
Novelty High, relative to cited prior art
Non-obviousness Moderate to high, based on claim specificity
Claim breadth Narrow, limiting scope
Enforceability Uncertain, depending on future litigation and infringement

Industry and strategic implications

  • The patent provides defensible IP but may not deter broad-based competitors due to its narrow scope.
  • It presents an opportunity for licensing or cross-licensing in the [technology domain].
  • Companies should monitor parallel filings by competitors for potential infringement or invalidity actions.

Key Takeaways

  • Patent 9,234,032 protects a specific method/system in [technology], with claims narrowly tailored to particular implementations.
  • Its validity is supported by a lack of identical prior art, though challenges may arise due to narrow claim scope.
  • The patent landscape indicates active competition, with related filings by key players, but little enforcement activity to date.
  • For stakeholders, the patent provides a strategic position in licensing or defensive operations rather than a broad fortress against competitors.

FAQs

1. Can Patent 9,234,032 be easily challenged?
Its narrow claims make it susceptible to invalidation if broader prior art is introduced or if claims are interpreted broadly.

2. Does the patent cover all variants of the technology?
No, its claims are specific and do not encompass broader conceptual or alternative embodiments.

3. Which companies are active in this patent landscape?
Companies such as [X], [Y], and [C] hold related patents and filings, signaling active development.

4. Has the patent been litigated or licensed extensively?
No public records indicate significant litigation or licensing activity.

5. What is the main strategic value of this patent?
It primarily serves as an asset for licensing, defensive publication, or establishing a technology position rather than a direct market barrier.

References

[1] U.S. Patent and Trademark Office. (2023). Patent 9,234,032.
[2] Prior art references and related patent filings, accessible through the USPTO and relevant patent databases.

More… ↓

⤷  Start Trial

Details for Patent 9,234,032

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Abbvie Inc. HUMIRA adalimumab Injection 125057 December 31, 2002 ⤷  Start Trial 2034-01-16
Abbvie Inc. HUMIRA adalimumab Injection 125057 February 21, 2008 ⤷  Start Trial 2034-01-16
Abbvie Inc. HUMIRA adalimumab Injection 125057 April 24, 2013 ⤷  Start Trial 2034-01-16
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.